Ocrelizumab and Rituximab Demonstrate Similar Safety, Efficacy in Treatment of Multiple Sclerosis
Treatment with either rituximab and ocrelizumab, 2 FDA-approved therapies that target CD20, resulted in similar odds of experiencing a clinical…
Peace out: Roche’s Genentech adopts V hand signal in next-gen Ocrevus campaign for multiple sclerosis
Beth Snyder Bulik -Senior Editor The two-finger V sign debuted in Roche’s Genentech first TV commercial for multiple sclerosis treatment…
Stuart Schlossman
Does Ocrelizumab Limit Multiple Sclerosis Progression? Current Evidence from Clinical, MRI, and Fluid Biomarkers – PubMed
Monica Margoni 1 2, Paolo Preziosa 1 3, Paola Tortorella 4, Massimo Filippi 1 3 5 6 7, Maria A Rocca 8 9 10 Affiliations expand PMID: 35668317 DOI: 10.1007/s13311-022-01252-5 Abstract Multiple sclerosis (MS) is a chronic inflammatory, demyelinating,…
Stuart Schlossman
MS patients treated with rituximab may receive COVID-19 vaccine as soon as possible
May 17, 2022 Rituximab-treated patients with MS may be vaccinated for COVID-19 as soon as possible, researchers reported in JAMA Network…
Stuart Schlossman
New Data for Genentech’s Ocrevus (Ocrelizumab) Show Benefit in Disability Progression and Cognitive Decline in Both Secondary Progressive and Primary Progressive Multiple Sclerosis
75% of patients with secondary progressive multiple sclerosis (SPMS) and primary progressive MS (PPMS) achieved no evidence of progression…
Stuart Schlossman
Ocrelizumab Data Go Against Traditional Conceptions of Wearing Off Effect
November 18, 2021 – Marco Meglio Ilya Kister, MD, professor of neurology, NYU Grossman School of Medicine, discussed his surprising…
Stuart Schlossman
Genentech to Present New Data on Ocrevus (ocrelizumab) in Multiple Sclerosis and Enspryng (satralizumab-mwge) in Neuromyelitis Optica Spectrum Disorder at ECTRIMS 2021
Ocrevus data to show sustained reduction in disability progression through 8 years for primary progressive multiple sclerosis (PPMS) and 7.5…
Stuart Schlossman
1 Year of Ocrevus Not Linked to Higher Risk of Brain Infection PML
By Steve Bryson PhD on Oct 07, 2021 One year of Ocrevus (ocrelizumab) treatment does not increase the risk for a rare…
Stuart Schlossman
B-Cell Depletion May Indicate Reduced COVID-19 Antibody Response Among Patients With MS
New research demonstrates that patients with multiple sclerosis (MS) who were asymptomatic for COVID-19 had lower antibody levels against…
Stuart Schlossman
MS Therapies That Deplete B-cells Appear to Work Against COVID Immunity
MAY 14, 2021 BY STEVE BRYSON PHD Click HERE to Subscribe for the MS Beacon eNewsletter! B-cell-depleting…
Stuart Schlossman
